US group questions human embryo research, calls for rules
By DPA,
Deutsche Presse-Agentur [cites Marcy Darnovsky]
| 05. 14. 2008
A US public interest group has called for the US to set up national bioethics standards and regulations on embryonic research after a group of scientists in New York State produced a genetically-engineered embryo, dpa reported.
The Center for Genetics and Society, located in Oakland, California, said Tuesday the need for such standards was clear after the research at Cornell University was brought to light by a London newspaper over the weekend. Britain is in the process of revamping its genetic research laws.
Marcy Darnovsky of the Center for Genetics and Society told Deutsche Presse-Agentur dpa that the US urgently needs federal bioethical standards and a regulatory panel similar to those in Canada and Britain or even Germany, which has some of the most stringent rules on genetic research.
"The prospect of genetic technology being used to introduce new types of genetic inequality and social division, to create genetically-enhanced children is the core of our concern," Darnovsky said.
A brief account of the study by scientists at Cornell University was published in September 2007 in the journal Fertility and Sterility...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
